ABCB1

Summary

ABCB1 (ATP binding cassette subfamily B member 1, HGNC:40) is a protein-coding gene on chromosome 7q21.12, encoding ATP-dependent translocase ABCB1 (P08183). Translocates drugs and phospholipids across the membrane. In precision oncology, ABCB1 I1145I confers sensitivity to Cisplatin + Carboplatin in Lung Non-small Cell Carcinoma (CIViC Level B); 5 further curated variant–drug associations are listed below.

The membrane-associated protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes. ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20, White). This protein is a member of the MDR/TAP subfamily. Members of the MDR/TAP subfamily are involved in multidrug resistance. The protein encoded by this gene is an ATP-dependent drug efflux pump for xenobiotic compounds with broad substrate specificity. It is responsible for decreased drug accumulation in multidrug-resistant cells and often mediates the development of resistance to anticancer drugs. This protein also functions as a transporter in the blood-brain barrier. Mutations in this gene are associated with colchicine resistance and Inflammatory bowel disease 13. Alternative splicing and the use of alternative promoters results in multiple transcript variants.

Source: NCBI Gene 5243 — RefSeq curated summary.

At a glance

• Gene–disease (curated): inflammatory bowel disease 13 (Limited, GenCC)
• GWAS associations: 8
• Clinical variants (ClinVar): 783 total — 6 pathogenic, 3 likely-pathogenic
• Phenotypes (HPO): 14
• Druggable target: yes — 119 molecules with ChEMBL bioactivity
• Precision-oncology evidence (CIViC): 6 curated variant–drug associations
• MANE Select transcript: NM_001348946

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:40
Approved symbol	ABCB1
Name	ATP binding cassette subfamily B member 1
Location	7q21.12
Locus type	gene with protein product
Status	Approved
Aliases	P-gp, CD243, GP170, ABC20, p-170, PGY1
Ensembl gene	ENSG00000085563
Ensembl biotype	protein_coding
OMIM	171050
Entrez	5243

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 15 protein_coding, 4 protein_coding_CDS_not_defined, 3 retained_intron

ENST00000265724, ENST00000416177, ENST00000475929, ENST00000476862, ENST00000482527, ENST00000483831, ENST00000488737, ENST00000491360, ENST00000496821, ENST00000543898, ENST00000622132, ENST00000890297, ENST00000890298, ENST00000890299, ENST00000890300, ENST00000890301, ENST00000890302, ENST00000890303, ENST00000890304, ENST00000890305, ENST00000961093, ENST00000961094

RefSeq mRNA: 4 — MANE Select: NM_001348946 NM_000927, NM_001348944, NM_001348945, NM_001348946

CCDS: CCDS5608

Canonical transcript exons

ENST00000622132 — 28 exons

Exon	Start	End
ENSE00000702254	87595766	87595814
ENSE00000702381	87566785	87566976
ENSE00002728072	87600117	87600190
ENSE00003233570	87570172	87570223
ENSE00003235942	87544823	87544999
ENSE00003264725	87550468	87550578
ENSE00003273072	87545863	87546024
ENSE00003287961	87541357	87541464
ENSE00003292673	87539268	87539345
ENSE00003304103	87550171	87550296
ENSE00003309678	87566070	87566241
ENSE00003349264	87550725	87550838
ENSE00003354968	87553761	87553932
ENSE00003361178	87561263	87561387
ENSE00003388874	87544129	87544275
ENSE00003391105	87549851	87550054
ENSE00003398270	87585512	87585680
ENSE00003462726	87520776	87520876
ENSE00003501292	87531294	87531497
ENSE00003509450	87536458	87536541
ENSE00003592234	87515231	87515428
ENSE00003592657	87505897	87506043
ENSE00003624471	87549348	87549518
ENSE00003648347	87509275	87509481
ENSE00003675090	87519326	87519466
ENSE00003693218	87516509	87516665
ENSE00003748181	87503017	87504449
ENSE00003748396	87600755	87600884

Expression profiles

Bgee: expression breadth ubiquitous, 232 present calls, max score 99.18.

FANTOM5 (CAGE): breadth broad, TPM avg 7.6662 / max 572.7827, expressed in 604 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
84724	7.2295	596
84729	0.3168	121
84730	0.1199	63

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right adrenal gland	UBERON:0001233	99.18	gold quality
right adrenal gland cortex	UBERON:0035827	99.16	gold quality
left adrenal gland cortex	UBERON:0035825	99.03	gold quality
left adrenal gland	UBERON:0001234	99.00	gold quality
adrenal cortex	UBERON:0001235	98.97	gold quality
adrenal gland	UBERON:0002369	97.50	gold quality
jejunal mucosa	UBERON:0000399	95.65	gold quality
mucosa of transverse colon	UBERON:0004991	95.28	gold quality
ileal mucosa	UBERON:0000331	93.54	gold quality
rectum	UBERON:0001052	93.23	gold quality
colonic mucosa	UBERON:0000317	92.80	gold quality
buccal mucosa cell	CL:0002336	92.11	gold quality
mucosa of sigmoid colon	UBERON:0004993	92.08	gold quality
small intestine Peyer’s patch	UBERON:0003454	91.55	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	90.58	gold quality
small intestine	UBERON:0002108	90.42	gold quality
duodenum	UBERON:0002114	90.38	gold quality
gall bladder	UBERON:0002110	89.66	gold quality
right lobe of liver	UBERON:0001114	88.89	gold quality
sural nerve	UBERON:0015488	88.73	gold quality
spinal cord	UBERON:0002240	88.17	gold quality
adult mammalian kidney	UBERON:0000082	87.89	gold quality
islet of Langerhans	UBERON:0000006	87.56	gold quality
liver	UBERON:0002107	87.27	gold quality
putamen	UBERON:0001874	87.09	gold quality
caudate nucleus	UBERON:0001873	86.81	gold quality
hypothalamus	UBERON:0001898	86.65	gold quality
amygdala	UBERON:0001876	86.09	gold quality
metanephros cortex	UBERON:0010533	85.92	gold quality
cingulate cortex	UBERON:0003027	85.38	gold quality

Single-cell (SCXA)

Detected in 14 experiment(s), a significant marker in 13.

Experiment	Marker?	Max mean expression
E-HCAD-25	yes	2520.90
E-GEOD-180759	yes	2355.54
E-HCAD-35	yes	2235.79
E-HCAD-30	yes	1485.56
E-CURD-89	yes	287.54
E-GEOD-81608	yes	137.46
E-GEOD-135922	yes	45.27
E-ANND-3	yes	6.62
E-GEOD-137537	yes	6.20
E-MTAB-10137	yes	5.12
E-GEOD-83139	yes	5.03
E-HCAD-31	yes	4.27
E-ENAD-27	yes	3.97
E-CURD-135	no	640.95

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): ABCC2, AHR, AP1, APEX1, APP, AR, ARNT, CDX2, CEBPA, CEBPB, CLOCK, CREB1, CTNNB1, DCTPP1, DLX4, DNMT1, E2F1, EAPP, EGR1, ELF4, EP300, ESR1, ESR2, ETS1, ETS2, ETV4, ETV6, FOS, FOXA2, FOXA3, FOXO1, FOXO3, GATA3, GLI1, GLI3, GRHL3, GTF2IRD1, HDAC1, HIF1A, HIPK2

miRNA regulators (miRDB)

34 targeting ABCB1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-12136	99.98	72.81	5713
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-552-5P	99.93	68.56	1583
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-3686	99.90	70.53	2432
HSA-MIR-4668-5P	99.79	70.58	3782
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-466	99.67	70.85	2863
HSA-MIR-5093	99.67	69.26	2291
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-4708-3P	99.51	67.99	870
HSA-MIR-5571-5P	99.49	66.99	1764
HSA-MIR-3915	99.45	68.49	1905
HSA-MIR-4652-3P	99.33	70.02	2742
HSA-MIR-12113	99.32	67.54	1072
HSA-MIR-593-3P	99.22	67.28	1327
HSA-MIR-146A-3P	99.13	68.99	1881
HSA-MIR-877-3P	99.09	68.10	1637
HSA-MIR-455-3P	98.94	67.68	878
HSA-MIR-491-3P	98.88	68.86	1224
HSA-MIR-935	98.82	69.36	1072
HSA-MIR-6895-3P	98.79	65.69	996
HSA-MIR-4539	98.78	67.18	888
HSA-MIR-12125	98.59	67.54	1044

Literature-anchored findings (GeneRIF, showing 40)

• Overall, our data suggest that the MDR1 (official symbol of ABCB1) 3’ UTR does not behave as an active destabilizing element in HepG2 cells. (PMID:10441477)
• Oligonucleotides inhibit mdr1 induction in Hela cells. (PMID:11563129)
• serum concentration of digoxin after single oral administration was lower in the subjects harboring a mutant allele (C3435T) at exon 26 of the MDR1 gene (PMID:11697464)
• Expression in nasopharyngeal carcinoma (PMID:11727264)
• Expression in nasopharyngeal carcinoma (PMID:11727264)
• No apparent changes were observed between controls and Down Syndrome in levels of Pgp in all brain regions examined. (PMID:11771758)
• role in transporting endogenous opioid peptides (PMID:11786185)
• The in vitro induction of apoptosis was not associated with expression of p-gp expression in acute lymphoblastic leukaemia and non-Hodgkin’s lymphoma in children. (PMID:11855781)
• Precipitous release [observed] of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation (PMID:11865062)
• Gene expression of P-gp and P26-bcl-2 is correlated with the tumor grade level of non-Hodgkin’s lymphoma. (PMID:11877091)
• cysteine-scanning mutagenesis and cross-linking studies to identify residues that are exposed to the drug-binding site upon vanadate trapping (PMID:11891276)
• involved in the drug resistance mechanism of tumors (PMID:11925925)
• findings suggest that Tax-related drug resistance of ATL cells is due to LRP and not MDR1, as reported previously. (PMID:11937269)
• Significance of P-glycoprotein expression in childhood malignant tumors: correlation between the level of P-glycoprotein expression and tumor histology, clinical outcome, use of therapy, relapse rate and metastatic disease was determined (PMID:11949840)
• Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. (PMID:11960367)
• Functional MDR1 polymorphisms (G2677T and C3435T) and TCF4 mutations in colorectal tumors with high microsatellite instability (PMID:11980438)
• no difference of expression between diagnosis and relapse of AML; not associated with clinical resistant disease in AML (PMID:11986944)
• The misfolding of P-gp in E. coli is due to the misrecognition of multiple P-gp sequences as topogenic signals. Thus, the alternative transmembrane topologies reported for P-gp in E. coli are artefacts of the heterologous expression system used. (PMID:11989822)
• Review.Functional polymorphisms of the human multidrug resistance (MDR1) gene: correlate with P glycoprotein expression and activity in vivo. (PMID:11990778)
• Review. In the current model, both MDR1 catalytic sites are active and ATP is hydrolyzed alternatively, triggering conformational changes resulting in drug transport at one site and re-setting the initial hig-affinity conformation at the other. (PMID:11990782)
• Association of specific cytogenetic aberrations with mdr1 gene expression in adult myeloid leukemia (PMID:12010657)
• mutations and functional polymorphisms in multidrug resistance 1 gene: correlation with microsatellite instability and lymphoid infiltration in colorectal cancers (PMID:12011154)
• The known functional MDR1 gene polymorphisms are not major determinants of P-glycoprotein function in CD34+ hematopoietic stem cells. (PMID:12031911)
• hydrolysis of linker region modulates ATPase function (PMID:12055198)
• Common MDR1 coding polymorphisms result in P-gps with a cell surface distribution and function similar to wild-type P-gp. (PMID:12065748)
• Introduction of the most common cystic fibrosis mutation (Delta F508) into human P-glycoprotein disrupts packing of the transmembrane segments (PMID:12070134)
• Coexpression of P-glycoprotein, Ets-1, and p53 in oral carcinoma is associated with poor prognosis (PMID:12073053)
• directly interacts with several tyrosine kinase inhibitors (PMID:12084474)
• Association of the P-glycoprotein transporter MDR1(C3435T) polymorphism with the susceptibility to renal epithelial tumors. Association between T allele frequency and the occurrence of tumors. The highest risk for homozygote TT allele carriers. (PMID:12089380)
• Stimulation of T cells resulted in the preferential retention of the photosensitizer TH9402 transported by P-GP in activated T cells, both CD4+ and CD8+. (PMID:12091325)
• The preferential expression of a mutant allele of the amplified MDR1 (ABCB1) gene has been investigated in drug-resistant variants of human sarcoma. (PMID:12112526)
• MRP1 is demonstrated to play a constitutive role in the intrinsic chemoresistance of gliomas and their normal cell counterpart. (PMID:12125964)
• MDR1 protein expression is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia. (PMID:12130511)
• multidrug transporter, P-glycoprotein, actively mediates cholesterol redistribution in the cell membrane (PMID:12145328)
• Review. Pgp has a drug-independent role in the apoptosis inhibition of AML blasts perhaps by modulation of cytokine efflux, signalling lipids and intracellular pH. (PMID:12152989)
• Results show efficient GTP hydrolysis by the N-terminal nucleotide binding domain (NBD1) of Pgp, and a minor role of phosphorylation in the control of Pgp NBD1 ATPase activity. (PMID:12163030)
• data strongly support the hypothesis that strong LD between the neutral SNP exon 26 3435C>T and a nearby unobserved causal SNP underlies the observed associations between the neutral SNP and MDR1 functional differences. (PMID:12172212)
• the C3435T polymorphism of MDR1 was suggested to correlate with the enterocyte expression of CYP3A4 rather than Pgp linking unknown genetic variation in CYP3A4 gene. (PMID:12172213)
• correlation of gene expression with histopathological findings and clinical outcome in ovarian and breast cancer patients (PMID:12174914)
• MDR1 exon 21 and exon 26 polymorphisms are related to steroid weaning in a pediatric heart transplant population (PMID:12175731)

Cross-species orthologs

12 orthologs

Organism	Symbol	Gene ID
mus_musculus	Abcb1b	ENSMUSG00000028970
mus_musculus	Abcb1a	ENSMUSG00000040584
rattus_norvegicus	Abcb1a	ENSRNOG00000008012
caenorhabditis_elegans		WBGENE00001817
caenorhabditis_elegans		WBGENE00001818
caenorhabditis_elegans		WBGENE00003995
caenorhabditis_elegans		WBGENE00004000
caenorhabditis_elegans		WBGENE00004001
caenorhabditis_elegans		WBGENE00004002
caenorhabditis_elegans		WBGENE00004003
caenorhabditis_elegans		WBGENE00004006
caenorhabditis_elegans		WBGENE00004008

Paralogs (10): ABCB5 (ENSG00000004846), ABCB4 (ENSG00000005471), ABCB11 (ENSG00000073734), ABCB6 (ENSG00000115657), ABCB7 (ENSG00000131269), ABCB10 (ENSG00000135776), ABCB9 (ENSG00000150967), TAP1 (ENSG00000168394), ABCB8 (ENSG00000197150), TAP2 (ENSG00000204267)

Protein

Protein identifiers

ATP-dependent translocase ABCB1 — P08183 (reviewed: P08183)

Alternative names: ATP-binding cassette sub-family B member 1, Multidrug resistance protein 1, P-glycoprotein 1, Phospholipid transporter ABCB1

All UniProt accessions (3): P08183, A4D1D2, E7EWT8

UniProt curated annotations — full annotation on UniProt →

Function. Translocates drugs and phospholipids across the membrane. Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins. Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.

Subunit / interactions. Interacts with PSMB5. Finds in a complex with ABCB1, TFPI2 and PPP2R3C; leading to the dephosphorylation of ABCB1.

Subcellular location. Cell membrane. Apical cell membrane. Cytoplasm.

Tissue specificity. Expressed in small intestine. Expressed in liver, kidney and brain.

Disease relevance. Inflammatory bowel disease 13 (IBD13) [MIM:612244] A chronic, relapsing inflammation of the gastrointestinal tract with a complex etiology. It is subdivided into Crohn disease and ulcerative colitis phenotypes. Crohn disease may affect any part of the gastrointestinal tract from the mouth to the anus, but most frequently it involves the terminal ileum and colon. Bowel inflammation is transmural and discontinuous; it may contain granulomas or be associated with intestinal or perianal fistulas. In contrast, in ulcerative colitis, the inflammation is continuous and limited to rectal and colonic mucosal layers; fistulas and granulomas are not observed. Both diseases include extraintestinal inflammation of the skin, eyes, or joints. Disease susceptibility is associated with variants affecting the gene represented in this entry. Encephalopathy, acute transient (ENPAT) [MIM:620950] An autosomal recessive neurologic disorder triggered by specific drugs, or acute febrile or afebrile illness. Clinical features include encephalopathy, ataxia, spasticity, pyramidal signs, diplopia, vomiting, and coma. Symptoms fully resolve within few days. The disease is caused by variants affecting the gene represented in this entry.

Activity regulation. Translocase activity is inhibited by verapamil and is sensitive to energy depletion. Inhibited by nicardipine. Inhibited by PSC833. Inhibited by vanadate. C1orf115 regulates drug efflux through modulation of ABCB1 localization and activity. Not inhibited by amantadine.

Polymorphism. Genetic variation in ABCB1 may play a role in patients who do not respond to drug treatment.

Similarity. Belongs to the ABC transporter superfamily. ABCB family. Multidrug resistance exporter (TC 3.A.1.201) subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
P08183-1	1	yes
P08183-2	2

RefSeq proteins (4): NP_000918, NP_001335873, NP_001335874, NP_001335875* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003439	ABC_transporter-like_ATP-bd	Domain
IPR003593	AAA+_ATPase	Domain
IPR011527	ABC1_TM_dom	Domain
IPR017871	ABC_transporter-like_CS	Conserved_site
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR036640	ABC1_TM_sf	Homologous_superfamily
IPR039421	Type_1_exporter	Family

Pfam: PF00005, PF00664

Enzyme classification (BRENDA):

• EC 7.6.2.2 — ABC-type xenobiotic transporter (BRENDA: 49 organisms, 716 substrates, 471 inhibitors, 280 Km, 31 kcat entries)
• EC 7.6.2.3 — ABC-type glutathione-S-conjugate transporter (BRENDA: 8 organisms, 145 substrates, 63 inhibitors, 16 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

75 substrates with measured Km, best-characterized 15. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.0009–9	105
VERAPAMIL/IN	0.0006–0.0058	11
VINBLASTINE/IN	0.0002–0.1455	11
ESTRADIOL 17-BETA-D-GLUCURONIDE/IN	0.013–0.17	7
LEUKOTRIENE C4/IN	—	7
METHOTREXATE/IN	0.24–0.776	6
NICARDIPINE/IN	0.0004–0.0026	6
PROGESTERONE/IN	0.0038–0.0207	6
CYCLIC GUANOSINE MONOPHOSPHATE/IN	0.36–2	5
VERAPAMIL	0.0022–0.0115	5
ATP	0.0865–0.91	5
COLCHICINE/IN	0.037–0.72	4
FOLIC ACID/IN	0.13–0.26	4
PACLITAXEL/IN	0.0007–0.0009	4
RHODAMINE 123/IN	0.0118–0.0354	4

Catalyzed reactions (Rhea), 4 shown:

• a 1,2-diacyl-sn-glycero-3-phosphoethanolamine(in) + ATP + H2O = a 1,2-diacyl-sn-glycero-3-phosphoethanolamine(out) + ADP + phosphate + H(+) (RHEA:36439)
• a 1,2-diacyl-sn-glycero-3-phosphocholine(out) + ATP + H2O = a 1,2-diacyl-sn-glycero-3-phosphocholine(in) + ADP + phosphate + H(+) (RHEA:38583)
• a sphingomyelin(in) + ATP + H2O = a sphingomyelin(out) + ADP + phosphate + H(+) (RHEA:38903)
• a beta-D-glucosyl-(1<->1’)-N-acylsphing-4-enine(in) + ATP + H2O = a beta-D-glucosyl-(1<->1’)-N-acylsphing-4-enine(out) + ADP + phosphate + H(+) (RHEA:38943)

UniProt features (162 total): helix 57, strand 32, sequence variant 26, topological domain 13, transmembrane region 12, turn 6, domain 4, glycosylation site 3, binding site 2, sequence conflict 2, chain 1, region of interest 1, compositionally biased region 1, modified residue 1, splice variant 1

Structure

Experimental structures (PDB)

24 structures.

PDB	Method	Resolution (Å)
8Y6H	ELECTRON MICROSCOPY	2.49
8Y6I	ELECTRON MICROSCOPY	2.54
7A69	ELECTRON MICROSCOPY	3.2
6C0V	ELECTRON MICROSCOPY	3.4
9CTG	ELECTRON MICROSCOPY	3.4
7A6F	ELECTRON MICROSCOPY	3.5
7O9W	ELECTRON MICROSCOPY	3.5
6FN1	ELECTRON MICROSCOPY	3.58
6QEX	ELECTRON MICROSCOPY	3.6
7A6C	ELECTRON MICROSCOPY	3.6
7A6E	ELECTRON MICROSCOPY	3.6
9CTC	ELECTRON MICROSCOPY	3.6
9CR8	ELECTRON MICROSCOPY	3.8
7A65	ELECTRON MICROSCOPY	3.9
8SB8	ELECTRON MICROSCOPY	3.9
8SBA	ELECTRON MICROSCOPY	3.9
9CTF	ELECTRON MICROSCOPY	3.9
8SB7	ELECTRON MICROSCOPY	4
8SA0	ELECTRON MICROSCOPY	4.1
8SB9	ELECTRON MICROSCOPY	4.1
6FN4	ELECTRON MICROSCOPY	4.14
8GMG	ELECTRON MICROSCOPY	4.3
8GMJ	ELECTRON MICROSCOPY	4.4
8SA1	ELECTRON MICROSCOPY	4.4

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P08183-F1	84.72	0.56

Antibody-complex structures (SAbDab): 11 — 6FN1, 6FN4, 6QEX, 7A65, 7A69, 7A6C, 7A6E, 7A6F, 7O9W, 8Y6H, 8Y6I

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (2): 427–434; 1070–1077

Post-translational modifications (1): 660

Glycosylation sites (3): 91, 94, 99

Function

Pathways and Gene Ontology

Reactome pathways

7 pathways

ID	Pathway
R-HSA-2161517	Abacavir transmembrane transport
R-HSA-382556	ABC-family protein mediated transport
R-HSA-9754706	Atorvastatin ADME
R-HSA-9757110	Prednisone ADME
R-HSA-2161522	Abacavir ADME
R-HSA-382551	Transport of small molecules
R-HSA-9748784	Drug ADME

MSigDB gene sets: 425 (showing top): VERHAAK_AML_WITH_NPM1_MUTATED_DN, GOBP_CIRCULATORY_SYSTEM_PROCESS, GOLDRATH_IMMUNE_MEMORY, LI_PROSTATE_CANCER_EPIGENETIC, GOBP_CELL_CYCLE_PHASE_TRANSITION, GOCC_CELL_SURFACE, SATO_SILENCED_BY_DEACETYLATION_IN_PANCREATIC_CANCER, GOBP_INORGANIC_ANION_TRANSPORT, BROWNE_HCMV_INFECTION_16HR_UP, LUCAS_HNF4A_TARGETS_UP, RIZKI_TUMOR_INVASIVENESS_3D_DN, BROWNE_HCMV_INFECTION_12HR_UP, GOBP_REGULATION_OF_MEMBRANE_LIPID_DISTRIBUTION, MORF_RAD51L3, GOBP_STEM_CELL_PROLIFERATION

GO Biological Process (62): G2/M transition of mitotic cell cycle (GO:0000086), response to hypoxia (GO:0001666), placenta development (GO:0001890), xenobiotic metabolic process (GO:0006805), female pregnancy (GO:0007565), lactation (GO:0007595), circadian rhythm (GO:0007623), response to xenobiotic stimulus (GO:0009410), hormone transport (GO:0009914), response to progesterone (GO:0032570), response to vitamin A (GO:0033189), response to vitamin D (GO:0033280), response to glucagon (GO:0033762), maintenance of blood-brain barrier (GO:0035633), cellular response to mycotoxin (GO:0036146), daunorubicin transport (GO:0043215), phospholipid translocation (GO:0045332), response to cadmium ion (GO:0046686), terpenoid transport (GO:0046865), intestinal absorption (GO:0050892), transmembrane transport (GO:0055085), establishment of blood-brain barrier (GO:0060856), transepithelial transport (GO:0070633), cellular response to external biotic stimulus (GO:0071217), cellular response to lipopolysaccharide (GO:0071222), cellular response to antibiotic (GO:0071236), cellular response to alkaloid (GO:0071312), cellular response to tumor necrosis factor (GO:0071356), cellular response to estradiol stimulus (GO:0071392), cellular hyperosmotic salinity response (GO:0071475), cellular response to dexamethasone stimulus (GO:0071549), stem cell proliferation (GO:0072089), response to thyroxine (GO:0097068), response to alcohol (GO:0097305), response to antineoplastic agent (GO:0097327), ceramide translocation (GO:0099040), export across plasma membrane (GO:0140115), transport across blood-brain barrier (GO:0150104), protein localization to bicellular tight junction (GO:1902396), response to glycoside (GO:1903416)

GO Molecular Function (18): ATP binding (GO:0005524), ABC-type xenobiotic transporter activity (GO:0008559), efflux transmembrane transporter activity (GO:0015562), ATP hydrolysis activity (GO:0016887), transmembrane transporter activity (GO:0022857), ubiquitin protein ligase binding (GO:0031625), ATPase-coupled transmembrane transporter activity (GO:0042626), xenobiotic transmembrane transporter activity (GO:0042910), carboxylic acid transmembrane transporter activity (GO:0046943), phosphatidylcholine floppase activity (GO:0090554), phosphatidylethanolamine flippase activity (GO:0090555), ceramide floppase activity (GO:0099038), floppase activity (GO:0140328), phosphatidylethanolamine floppase activity (GO:0140341), nucleotide binding (GO:0000166), protein binding (GO:0005515), ATPase-coupled intramembrane lipid carrier activity (GO:0140326), ABC-type transporter activity (GO:0140359)

GO Cellular Component (9): cytoplasm (GO:0005737), plasma membrane (GO:0005886), cell surface (GO:0009986), membrane (GO:0016020), apical plasma membrane (GO:0016324), brush border membrane (GO:0031526), extracellular exosome (GO:0070062), external side of apical plasma membrane (GO:0098591), apical part of cell (GO:0045177)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Drug ADME	3
Abacavir ADME	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
transmembrane transporter activity	3
ATP-dependent activity	3
response to vitamin	2
response to lipid	2
floppase activity	2
apical plasma membrane	2
mitotic cell cycle	1
mitotic cell cycle phase transition	1
cell cycle G2/M phase transition	1
response to stress	1
response to decreased oxygen levels	1
animal organ development	1
metabolic process	1
cellular response to xenobiotic stimulus	1
multi-organism reproductive process	1
multi-multicellular organism process	1
body fluid secretion	1
mammary gland development	1
milk ejection reflex	1
rhythmic process	1
response to chemical	1
transport	1
regulation of hormone levels	1
response to steroid hormone	1
response to ketone	1
response to oxygen-containing compound	1
response to peptide hormone	1
tissue homeostasis	1
response to mycotoxin	1
cellular response to toxic substance	1
nitrogen compound transport	1
glycoside transport	1
phospholipid transport	1
lipid translocation	1
response to metal ion	1
isoprenoid transport	1
digestive system process	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1

Protein interactions and networks

STRING

4233 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ABCB1	CYP3A5	P20815	914
ABCB1	SLCO1B1	Q9Y6L6	877
ABCB1	CYP3A4	P05184	876
ABCB1	CYP2C19	P33259	850
ABCB1	SLCO1B3	Q9NPD5	836
ABCB1	NR1I2	O75469	833
ABCB1	ABCF2	Q9UG63	804
ABCB1	PPIG	Q13427	802
ABCB1	STAT3	P40763	800
ABCB1	MRPS7	Q9Y2R9	776
ABCB1	CYP2D6	P10635	767
ABCB1	MVP	Q14764	751
ABCB1	CYP2C9	P11712	728
ABCB1	CYP2B6	P20813	727
ABCB1	SLC22A1	O15245	705

IntAct

75 interactions, top by confidence:

A	B	Type	Score
CD9	ADAM10	psi-mi:“MI:0914”(association)	0.750
ASPH	STXBP3	psi-mi:“MI:0914”(association)	0.640
TRDN	TMEM223	psi-mi:“MI:0914”(association)	0.640
ARRDC4	WWP2	psi-mi:“MI:0914”(association)	0.530
LGALS3	PODXL	psi-mi:“MI:0914”(association)	0.530
RNF2	ABCB1	psi-mi:“MI:0915”(physical association)	0.510
ABCB1	RNF2	psi-mi:“MI:0915”(physical association)	0.510
HMMR	ABCB1	psi-mi:“MI:0915”(physical association)	0.400
ABCB1	LAPTM4B	psi-mi:“MI:0915”(physical association)	0.400
GPC1	SNAP23	psi-mi:“MI:0915”(physical association)	0.400
GPC1	GANAB	psi-mi:“MI:0915”(physical association)	0.400
CD4	ABCB1	psi-mi:“MI:0915”(physical association)	0.370
ABCB1	BCCIP	psi-mi:“MI:0915”(physical association)	0.370
ABCB1	MAPKAP1	psi-mi:“MI:0915”(physical association)	0.370
APP	RTL1	psi-mi:“MI:0914”(association)	0.350
LGALS3	PODXL	psi-mi:“MI:0914”(association)	0.350
MYC		psi-mi:“MI:0914”(association)	0.350
CANX	HLA-A	psi-mi:“MI:0914”(association)	0.350
RAB11A	SCAMP1	psi-mi:“MI:0914”(association)	0.350
TTMP	TMEM223	psi-mi:“MI:0914”(association)	0.350
TTYH1	TMEM223	psi-mi:“MI:0914”(association)	0.350
EDAR	UPK3BL1	psi-mi:“MI:0914”(association)	0.350
CCR6	GPR89A	psi-mi:“MI:0914”(association)	0.350
TMEM169	GPR89A	psi-mi:“MI:0914”(association)	0.350
TAS2R19	STXBP3	psi-mi:“MI:0914”(association)	0.350
MARCHF1	STXBP3	psi-mi:“MI:0914”(association)	0.350
SAAL1	QSOX1	psi-mi:“MI:0914”(association)	0.350
LGALS9B	ABCC4	psi-mi:“MI:0914”(association)	0.350

BioGRID (118): ABCB1 (Two-hybrid), ABCB1 (Affinity Capture-MS), ABCB1 (Affinity Capture-MS), ABCB1 (Biochemical Activity), ABCB1 (Affinity Capture-MS), ABCB1 (Affinity Capture-MS), ABCB1 (Affinity Capture-MS), ABCB1 (Proximity Label-MS), ABCB1 (Proximity Label-MS), ABCB1 (Proximity Label-MS), ABCB1 (Proximity Label-MS), CAV1 (Affinity Capture-Western), ABCB1 (Affinity Capture-Western), ABCB1 (Proximity Label-MS), ABCB1 (Proximity Label-MS)

ESM2 similar proteins: A0A059JJ46, A0A1U8QG99, B5X0E4, B8K1W2, F2PRR1, F2RP52, H6TB12, O70127, O95342, P06795, P08183, P16876, P16877, P21439, P21440, P21447, P21449, P23174, P34712, P34713, P43245, P91660, Q00449, Q00748, Q08201, Q0WML0, Q2M3G0, Q54JR2, Q6Q876, Q6YUU5, Q7FB56, Q8LPK2, Q9C7F2, Q9C7F8, Q9FHF1, Q9FNU2, Q9FWX8, Q9LHD1, Q9LHK4, Q9LJX0

Diamond homologs: A0A059JJ46, A0A059JK44, A0A095C325, A0A0D1BUH6, A0A1U8QG99, A0A1U9YI12, A0A2P1AAV1, A0A348AXX9, A1KF14, B2GUP8, B2KWH4, B5X0E4, B8K1W2, F2PRR1, F2Q5G0, F2RP52, F2RPA4, F2SQT8, F2T1C4, G5EG61, H6TB12, J9VF33, K3VYH8, O53645, O70127, O80725, O95342, P06795, P08183, P0CU83, P16875, P16876, P16877, P21439, P21440, P21447, P21448, P21449, P23174, P34712

SIGNOR signaling

36 interactions.

A	Effect	B	Mechanism
CEBPB	“up-regulates quantity by expression”	ABCB1	“transcriptional regulation”
E2F1	“up-regulates quantity by expression”	ABCB1	“transcriptional regulation”
EAPP	“up-regulates quantity by expression”	ABCB1	“transcriptional regulation”
EGR1	“up-regulates quantity by expression”	ABCB1	“transcriptional regulation”
SP1	“up-regulates quantity by expression”	ABCB1	“transcriptional regulation”
YBX1	“up-regulates quantity by expression”	ABCB1	“transcriptional regulation”
ETS1	“up-regulates quantity by expression”	ABCB1	“transcriptional regulation”
HDAC1	“down-regulates quantity by repression”	ABCB1	“transcriptional regulation”
UHRF1	“down-regulates quantity by repression”	ABCB1	“transcriptional regulation”
HIF1A	“up-regulates quantity by expression”	ABCB1	“transcriptional regulation”
JUN	“up-regulates quantity by expression”	ABCB1	“transcriptional regulation”
MYCN	“down-regulates quantity by repression”	ABCB1	“transcriptional regulation”
NfKb-p65/p50	“up-regulates quantity by expression”	ABCB1	“transcriptional regulation”
NR1I2	“up-regulates quantity by expression”	ABCB1	“transcriptional regulation”
SIRT1	“up-regulates quantity by expression”	ABCB1	“transcriptional regulation”
TCF4	“up-regulates quantity by expression”	ABCB1	“transcriptional regulation”
TP53	“down-regulates quantity by repression”	ABCB1	“transcriptional regulation”
YBX1	“down-regulates quantity by repression”	ABCB1	“transcriptional regulation”
regorafenib	“down-regulates activity”	ABCB1	“chemical inhibition”
POLR1H	“up-regulates quantity by expression”	ABCB1	“transcriptional regulation”
DCTPP1	“up-regulates quantity by expression”	ABCB1	“transcriptional regulation”
PPP5C	“down-regulates activity”	ABCB1	dephosphorylation
PKA	“up-regulates activity”	ABCB1	dephosphorylation
PIM1	“up-regulates activity”	ABCB1	dephosphorylation
PKC	“up-regulates activity”	ABCB1	dephosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 99 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
SLC transporter disorders	7	21.3×	4e-06
R-HSA-425366	7	18.9×	6e-06
R-HSA-425393	8	15.5×	4e-06
Disorders of transmembrane transporters	7	14.6×	3e-05
SLC-mediated transmembrane transport	15	13.2×	1e-10
Transport of small molecules	18	6.8×	1e-08

GO biological processes:

GO term	Partners	Fold	FDR
amino acid transport	6	20.8×	3e-04
sodium ion transport	6	18.1×	3e-04
transport across blood-brain barrier	7	13.9×	3e-04
monoatomic ion transport	6	10.4×	5e-03
exocytosis	6	10.1×	5e-03

Disease & clinical

Cancer significance

Clinical variants and AI predictions

ClinVar

783 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	6
Likely pathogenic	3
Uncertain significance	110
Likely benign	27
Benign	14

Top pathogenic / likely-pathogenic (9)

Variant ID	HGVS	Classification
13698	NM_001348946.2(ABCB1):c.554G>T (p.Gly185Val)	Pathogenic
3340125	NM_001348946.2(ABCB1):c.2380C>T (p.Arg794Ter)	Pathogenic
3340126	NM_000927.4:c.3053-3056del	Pathogenic
3340127	NM_001348946.2(ABCB1):c.2786+1G>T	Pathogenic
3340128	ABCB1, GLN1182TER	Pathogenic
3391895	GRCh37/hg19 7q11.23-21.3(chr7:74666254-97791584)x1	Pathogenic
1164001	NM_001348946.2(ABCB1):c.2678C>A (p.Ser893Tyr)	Likely pathogenic
151098	GRCh38/hg38 7q21.12-21.2(chr7:87379476-91731873)x1	Likely pathogenic
979629	GRCh37/hg19 7q21.12(chr7:86907024-87154688)x1	Likely pathogenic

SpliceAI

5520 predictions. Top by Δscore:

Variant	Effect	Δscore
7:87509270:CTTA:C	donor_loss	1.0000
7:87509271:TTACA:T	donor_loss	1.0000
7:87509272:TACAT:T	donor_loss	1.0000
7:87509273:A:AC	donor_gain	1.0000
7:87509273:A:AT	donor_loss	1.0000
7:87509274:C:A	donor_loss	1.0000
7:87509274:C:CA	donor_gain	1.0000
7:87509274:CA:C	donor_gain	1.0000
7:87509274:CAT:C	donor_gain	1.0000
7:87509274:CATT:C	donor_gain	1.0000
7:87509274:CATTA:C	donor_gain	1.0000
7:87509336:T:TA	donor_gain	1.0000
7:87509477:AGCAG:A	acceptor_gain	1.0000
7:87509478:GCAG:G	acceptor_gain	1.0000
7:87509479:CAG:C	acceptor_gain	1.0000
7:87509479:CAGC:C	acceptor_gain	1.0000
7:87509480:AG:A	acceptor_gain	1.0000
7:87509481:GCT:G	acceptor_loss	1.0000
7:87509482:C:CC	acceptor_gain	1.0000
7:87515230:CCA:C	donor_gain	1.0000
7:87515236:T:A	donor_gain	1.0000
7:87515237:C:A	donor_gain	1.0000
7:87515424:GTGTT:G	acceptor_gain	1.0000
7:87515425:TGTT:T	acceptor_gain	1.0000
7:87515426:GTT:G	acceptor_gain	1.0000
7:87515427:TT:T	acceptor_gain	1.0000
7:87515429:C:CC	acceptor_gain	1.0000
7:87515432:C:CT	acceptor_gain	1.0000
7:87515433:A:T	acceptor_gain	1.0000
7:87515434:A:AC	acceptor_gain	1.0000

AlphaMissense

8415 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:87505913:T:A	D1207V	1.000
7:87505987:T:A	Q1182H	1.000
7:87505987:T:G	Q1182H	1.000
7:87504388:C:G	R1233P	0.999
7:87504390:G:C	H1232Q	0.999
7:87504390:G:T	H1232Q	0.999
7:87504392:G:C	H1232D	0.999
7:87504445:A:T	V1214D	0.999
7:87505912:A:C	D1207E	0.999
7:87505912:A:T	D1207E	0.999
7:87505913:T:C	D1207G	0.999
7:87505913:T:G	D1207A	0.999
7:87505914:C:G	D1207H	0.999
7:87505916:A:G	L1206P	0.999
7:87505931:T:A	E1201V	0.999
7:87505985:C:G	R1183P	0.999
7:87506006:A:G	L1176P	0.999
7:87509410:C:A	Q1118H	0.999
7:87509410:C:G	Q1118H	0.999
7:87549462:C:A	Q537H	0.999
7:87549462:C:G	Q537H	0.999
7:87549980:C:A	Q475H	0.999
7:87549980:C:G	Q475H	0.999
7:87566106:A:C	S222R	0.999
7:87566106:A:T	S222R	0.999
7:87566108:T:G	S222R	0.999
7:87504389:G:C	R1233G	0.998
7:87504389:G:T	R1233S	0.998
7:87505903:A:C	S1210R	0.998
7:87505903:A:T	S1210R	0.998

dbSNP variants (sampled 300 via entrez): RS1000002062 (7:87660379 A>G), RS1000021614 (7:87539664 T>C), RS1000039130 (7:87685323 A>C,G), RS1000056048 (7:87660063 T>C), RS1000079458 (7:87706794 A>G), RS1000087240 (7:87678177 T>C), RS1000092742 (7:87631396 T>C), RS1000099209 (7:87578430 T>C,G), RS1000117457 (7:87508978 C>G), RS1000149378 (7:87571925 T>C), RS1000162630 (7:87650382 T>C), RS1000173307 (7:87577164 T>G), RS1000177536 (7:87692641 T>C,G), RS1000183002 (7:87705208 T>C), RS1000190530 (7:87556943 C>A,T)

Disease associations

OMIM: gene MIM:171050 | disease phenotypes: MIM:612244, MIM:600669, MIM:613659, MIM:620950

GenCC curated gene-disease

Disease	Classification	Inheritance
inflammatory bowel disease 13	Limited	Autosomal dominant

Mondo (6): inflammatory bowel disease 13 (MONDO:0012831), idiopathic generalized epilepsy (MONDO:0005579), gastric cancer (MONDO:0001056), epilepsy (MONDO:0005027), encephalopathy, acute transient (MONDO:0975801), hereditary breast ovarian cancer syndrome (MONDO:0003582)

Orphanet (1): Hereditary breast and/or ovarian cancer syndrome (Orphanet:145)

HPO phenotypes

14 total (14 of 14 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000651	Diplopia
HP:0001251	Ataxia
HP:0001257	Spasticity
HP:0001259	Coma
HP:0001347	Hyperreflexia
HP:0002013	Vomiting
HP:0002027	Abdominal pain
HP:0002037	Inflammation of the large intestine
HP:0002367	Visual hallucination
HP:0003621	Juvenile onset
HP:0004372	Reduced consciousness
HP:0006846	Acute encephalopathy
HP:0007256	Abnormal pyramidal sign

GWAS associations

8 associations (top):

Study	Trait	p-value
GCST003101_2	Bone mineral density (spine) and age at menarche	8.000000e-07
GCST003101_3	Bone mineral density (spine) and age at menarche	2.000000e-06
GCST004201_2	Gallbladder cancer	2.000000e-09
GCST008478_29	Neurological blood protein biomarker levels	6.000000e-13
GCST011316_1	Persistent chemotherapy-induced alopecia in breast cancer	4.000000e-08
GCST011707_2	Cerebral microbleeds	3.000000e-07
GCST90000025_352	Appendicular lean mass	3.000000e-11
GCST90013405_75	Liver enzyme levels (alanine transaminase)	5.000000e-33

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004703	age at menarche
EFO:0007701	spine bone mineral density
EFO:0010059	cerebral microbleeds
EFO:0004980	appendicular lean mass

MeSH disease descriptors (4)

Descriptor	Name	Tree numbers
D004827	Epilepsy	C10.228.140.490
D061325	Hereditary Breast and Ovarian Cancer Syndrome	C04.588.180.483; C04.588.322.455.431; C04.700.517; C12.050.351.500.056.630.705.431; C12.050.351.937.418.685.431; C12.100.250.056.630.705.431; C12.900.418.685.431; C16.320.700.517; C17.800.090.500.483; C19.344.410.431; C19.391.630.705.431
C562694	Epilepsy, Idiopathic Generalized (supp.)
C567384	Inflammatory Bowel Disease 13 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL3430875 (SELECTIVITY GROUP), CHEMBL4302 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

119 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,281,910 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL103	PROGESTERONE	4	162,141
CHEMBL104	CLOTRIMAZOLE	4	56,325
CHEMBL1064	SIMVASTATIN	4	123,163
CHEMBL1112	ARIPIPRAZOLE	4	24,205
CHEMBL114	SAQUINAVIR	4	39,899
CHEMBL1163	ATAZANAVIR	4	22,094
CHEMBL1172	DESLORATADINE	4	19,720
CHEMBL12713	SERTINDOLE	4	8,984
CHEMBL1292	CLOFAZIMINE	4	15,481
CHEMBL1294	QUINIDINE	4	71,943
CHEMBL1323	DARUNAVIR	4	15,382
CHEMBL1393	SPIRONOLACTONE	4	49,171
CHEMBL1423	PIMOZIDE	4	17,310
CHEMBL1480	FELODIPINE	4	30,761
CHEMBL1484	NICARDIPINE	4	30,866
CHEMBL1491	AMLODIPINE	4	39,495
CHEMBL1502	PANTOPRAZOLE	4	14,689
CHEMBL1503	OMEPRAZOLE	4	52,284
CHEMBL157101	KETOCONAZOLE	4	75,361
CHEMBL159	VINBLASTINE	4	412,636
CHEMBL160	CYCLOSPORINE	4
CHEMBL163	RITONAVIR	4
CHEMBL170	QUININE	4
CHEMBL17157	TERFENADINE	4
CHEMBL1726	NISOLDIPINE	4
CHEMBL1741	CLARITHROMYCIN	4
CHEMBL178	DAUNORUBICIN	4
CHEMBL2103875	TRAMETINIB	4
CHEMBL23	DILTIAZEM	4
CHEMBL2403108	CERITINIB	4

Clinical evidence (CIViC)

Drug × variant × indication: 6 predictive associations from 6 curated evidence items; also 2 prognostic.

Variant	Therapy	Indication	Effect	Level	CIViC
ABCB1 I1145I	Cisplatin + Carboplatin	Lung Non-small Cell Carcinoma	Sensitivity/Response	CIViC B	EID675
ABCB1 S893T	Paclitaxel	Ovarian Cancer	Sensitivity/Response	CIViC B	EID674
ABCB1 Overexpression	Bafetinib + Dasatinib	Chronic Myeloid Leukemia	Resistance	CIViC D	EID2681
ABCB1 Overexpression	Paclitaxel	Lung Non-small Cell Carcinoma	Resistance	CIViC D	EID944
EML4::ALK Fusion AND ABCB1 Overexpression	Lorlatinib + Alectinib	Lung Adenocarcinoma	Resistance	CIViC D	EID10016
EML4::ALK Fusion AND ABCB1 Overexpression	Ceritinib + Crizotinib	Lung Adenocarcinoma	Resistance	CIViC D	EID7869

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

249 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs10248420	Efficacy	3	amitriptyline;citalopram;paroxetine;venlafaxine	Depression
rs10248420	Efficacy	3	clozapine	Schizophrenia
rs10248420	Toxicity	3	olanzapine	Somnolence
rs10267099	Toxicity	3	atenolol	Hypertension
rs10280101	Efficacy	3	amitriptyline;citalopram;paroxetine;venlafaxine	Depression
rs1045642	Dosage	3	phenytoin
rs1045642	Toxicity	3	simvastatin	Hypercholesterolemia;Myalgia
rs1045642	Dosage	4	morphine	Pain;Pain;Postoperative
rs1045642	Efficacy	4	simvastatin
rs1045642	Efficacy	4	antiepileptics	Epilepsies;Partial;Epilepsy;Epilepsy;idiopathic generalized
rs1045642	Efficacy	4	pantoprazole	Helicobacter Infections
rs1045642	Efficacy	4	methotrexate	Acute lymphoblastic leukemia
rs1045642	Efficacy	4	methotrexate	Juvenile Rheumatoid Arthritis;Rheumatoid arthritis
rs1045642	Dosage	4	methadone	Heroin Dependence;Opioid-Related Disorders
rs1045642	Efficacy	4	paclitaxel	Breast Neoplasms;Neoplasms
rs1045642	Efficacy	4	docetaxel	Breast Neoplasms;Neoplasms
rs1045642	Toxicity	4	paclitaxel	Drug Toxicity;Neoplasms;Neutropenia;Peripheral Nervous System Diseases
rs1045642	Toxicity	3	atorvastatin	Coronary Artery Disease;Myalgia
rs1045642	Dosage,Metabolism/PK	4	tacrolimus	Organ Transplantation
rs1045642	Toxicity	3	sirolimus	Kidney Transplantation
rs1045642	Other	3	talinolol
rs1045642	Efficacy	3	anthracyclines and related substances;taxanes	Breast Neoplasms
rs1045642	Efficacy	3	tamoxifen	Breast Neoplasms
rs1045642	Efficacy	3	morphine	Pain
rs1045642	Other	3	rhodamine 123
rs1045642	Efficacy	3	vincristine	Acute lymphoblastic leukemia
rs1045642	Other	3	morphine	Pain
rs1045642	Efficacy	3	dexamethasone;doxorubicin;vincristine	Multiple Myeloma
rs1045642	Other	3	olanzapine	Psychotic Disorder
rs1045642	Efficacy,Toxicity	3	efavirenz;nelfinavir	HIV infectious disease
rs1045642	Toxicity	3	risperidone	Schizophrenia
rs1045642	Toxicity	3	tacrolimus	Kidney Transplantation
rs1045642	Other	3	HMG-CoA reductase inhibitors
rs1045642	Efficacy	3	phenobarbital	Epilepsy
rs1045642	Toxicity	3	methylprednisolone;prednisolone	Kidney Transplantation
rs1045642	Metabolism/PK	3	etoposide	Acute lymphoblastic leukemia
rs1045642	Metabolism/PK	3	cyclosporine	Transplantation
rs1045642	Metabolism/PK	3	daptomycin
rs1045642	Other	3	dicloxacillin
rs1045642	Toxicity	3	sorafenib	Hypertension;Renal Cell Carcinoma

PharmGKB variants

61 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs3842	ABCB1	3	4.12	3	olanzapine;efavirenz
rs868755	ABCB1		0.00	0
rs1045642	ABCB1	3	6.25	110	nevirapine;prednisone;tacrolimus;antiepileptics;paclitaxel;carbamazepine;dexamethasone;doxorubicin;vincristine;rhodamine 123;capecitabine;losartan;clozapine
rs1128503	ABCB1	3	6.00	43	cytarabine;sirolimus;cisplatin;cyclophosphamide;doxorubicin;methotrexate;vincristine;oxaliplatin;digoxin;methotrexate;risperidone;cyclosporine;tacrolimus;phenytoin
rs1186745	ABCB1		0.00	0
rs1186746	ABCB1		0.00	0
rs1922242	ABCB1	3	1.75	1	fluvastatin
rs2032582	ABCB1	3	5.25	48	paclitaxel;tacrolimus;dexamethasone;doxorubicin;vincristine;efavirenz;sirolimus;temsirolimus;doxorubicin;antiepileptics;carbamazepine;digoxin;simvastatin;atorvastatin
rs2032583	ABCB1	3	5.25	1	amitriptyline;antidepressants;citalopram;fluvoxamine;paroxetine;sertraline;venlafaxine
rs2032588	ABCB1		0.00	0
rs2229107	ABCB1		0.00	0
rs2229109	ABCB1	3	3.50	7	temozolomide;dexamethasone;lenalidomide;paclitaxel;tacrolimus;doxorubicin;methotrexate;prednisolone;vincristine;bleomycin;cyclophosphamide;doxorubicin;prednisone;rituximab;vincristine;vindesine;valganciclovir
rs2235013	ABCB1		0.00	0
rs2235015	ABCB1	3	1.00	1	amitriptyline;antidepressants;citalopram;paroxetine;venlafaxine
rs2235033	ABCB1		0.00	0
rs2235040	ABCB1	3	3.25	3	antidepressants;citalopram;fluvoxamine;paroxetine;sertraline;venlafaxine;amitriptyline;citalopram;paroxetine;venlafaxine;imatinib
rs2235047	ABCB1	4	-1.25	1	anthracyclines and related substances
rs2235048	ABCB1		0.00	0
rs2235067	ABCB1	3	2.75	1	amitriptyline;citalopram;paroxetine;venlafaxine
rs3213619	ABCB1	3	1.50	1	atenolol
rs3747802	ABCB1, RUNDC3B		0.00	0
rs3789243	ABCB1	3	3.50	1	antiepileptics
rs4148737	ABCB1	3	0.00	1	cisplatin;cyclophosphamide;doxorubicin;methotrexate;vincristine
rs4148739	ABCB1	3	2.75	2	amitriptyline;citalopram;fluoxetine;paroxetine;sertraline;venlafaxine;carbamazepine
rs4148740	ABCB1	3	2.75	2	amitriptyline;citalopram;paroxetine;venlafaxine;carbamazepine
rs4728709	ABCB1	3	3.00	2	olanzapine;vincristine
rs7787082	ABCB1	3	2.75	2	clozapine;amitriptyline;citalopram;paroxetine;venlafaxine
rs9282564	ABCB1	3	2.75	5	paclitaxel;morphine;tacrolimus;opioids;methadone
rs10248420	ABCB1	3	2.75	3	olanzapine;clozapine;amitriptyline;citalopram;paroxetine;venlafaxine
rs10267099	ABCB1, RUNDC3B	3	1.50	1	atenolol
rs10276036	ABCB1		0.00	0
rs10280101	ABCB1	3	2.75	1	amitriptyline;citalopram;paroxetine;venlafaxine
rs10280623	ABCB1		0.00	0
rs11983225	ABCB1	3	2.75	1	amitriptyline;citalopram;paroxetine;venlafaxine
rs12720067	ABCB1	3	2.75	1	amitriptyline;citalopram;paroxetine;venlafaxine
rs17160359	ABCB1, RUNDC3B	3	0.00	1	capecitabine;fluorouracil
rs28401781	ABCB1	3	0.00	1	citalopram;fluoxetine;paroxetine;sertraline
rs72552784	ABCB1	3	0.00	1	paclitaxel
rs4148738	ABCB1	3	2.75	2	apixaban;dabigatran
rs10234411	ABCB1		0.00	0

PharmGKB dosing guidelines

1 guidelines.

Source	Drug	Guideline	Dosing?	Recommendation?
RNPGx	methotrexate	Annotation of RNPGx Guideline for methotrexate and ABCB1, MTHFR, SLC19A1, SLCO1B1

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — ABCB subfamily

Most potent curated ligand interactions (9 total), top 9:

Ligand	Action	Affinity	Parameter
WS-898	Inhibition	8.3	pIC50
WS-917	Binding	8.3	pIC50
tariquidar	Inhibition	7.42	pIC50
elacridar	Inhibition	7.4	pKi
encequidar	Inhibition	7.28	pIC50
zosuquidar	Inhibition	7.23	pKi
valspodar	Inhibition	5.89	pKi
compound 14 [PMID: 30925062]	Competitive	5.76	pIC50
biricodar	Inhibition	5.3	pIC50

Binding affinities (BindingDB)

46 measured of 64 human assays (64 total across all organisms); most potent 46 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
CHEMBL5632630	EC50	12 nM
CHEMBL4552725	IC50	109 nM
CHEMBL1829396	KI	340 nM
CHEMBL1829520	KI	390 nM
CHEMBL1829518	KI	470 nM
CHEMBL1829521	KI	510 nM
nicotinic acid (1S,2R,4S,5R,6R,7S,9R,12R)-5-acetoxy-6-acetoxymethyl-7,12-bis-benzyloxy-2-hydroxy-2,10,10-trimethyl-11-oxa-tricyclo[7.2.1.01,6]dodec-4-yl ester	KI	580 nM
CHEMBL1829397	KI	590 nM
1beta-6alpha-15-triacetoxy–2beta,9alpha-dibenzoyloxydihydrobeta-agarofuran	KI	630 nM
nicotinic acid (1S,2R,4S,5R,6R,7S,9R,12R)-5-acetoxy-6-acetoxymethyl-7,12-bis-benzoyloxy-2,10,10-trimethyl-11-oxa-tricyclo[7.2.1.01,6]dodec-4-yl ester	KI	710 nM
furan-2-carboxylic acid (1S,2R,4S,5R,6R,7S,9R,12R)-4,5-diacetoxy-12-dodecanoyloxy-2-hydroxy-2,6,10,10-tetramethyl-11-oxa-tricyclo[7.2.1.01,6]dodec-7-yl ester	KI	800 nM
furan-2-carboxylic acid (1S,2R,4S,5R,6R,7S,9R,12R)-5-acetoxy-4-benzoyloxy-2-hydroxy-2,6,10,10-tetramethyl-12-pentyloxy-11-oxa-tricyclo[7.2.1.01,6]dodec-7-yl ester	KI	1000 nM
(1S,2R,4S,5R,6R,7S,9R,12R)-4,5-bis(acetyloxy)-6-[(acetyloxy)methyl]-7-(benzoyloxy)-2-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0^{1,6}]dodecan-12-yl benzoate	KI	1500 nM
Acetic acid (1S,2R,4S,5R,6S,7S,9R,12R)-12-acetoxy-6-acetoxymethyl-2,10,10-trimethyl-8-oxo-5,7-diphenoxy-11-oxa-tricyclo[7.2.1.01,6]dodec-4-yl ester	KI	1630 nM
benzoic acid (1S,2R,4S,5R,6R,7S,9R,12R)-4,5,12-triacetoxy-6-acetoxymethyl-2,10,10-trimethyl-11-oxa-tricyclo[7.2.1.01,6]dodec-7-yl ester	KI	2360 nM
(1S,2R,4S,5R,6R,7S,9R,12R)-4,5-bis(acetyloxy)-6-[(acetyloxy)methyl]-7-[(furan-2-yl)carbonyloxy]-2-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0^{1,6}]dodecan-12-yl furan-2-carboxylate	KI	2440 nM
Benzoic acid (1S,2R,4S,5R,6S,7S,9R,12R)-4,5,12-triacetoxy-6-acetoxymethyl-2,10,10-trimethyl-8-oxo-11-oxa-tricyclo[7.2.1.01,6]dodec-7-yl ester	KI	2540 nM
CHEMBL209247	IC50	2550 nM
CHEMBL2042913	IC50	2700 nM
CHEMBL2042912	IC50	2800 nM
furan-2-carboxylic acid (1S,2R,4S,5R,6R,7S,9R,12R)-4,5-diacetoxy-2-hydroxy-2,6,10,10-tetramethyl-12-pentyloxy-11-oxa-tricyclo[7.2.1.01,6]dodec-7-yl ester	KI	2810 nM
furan-2-carboxylic acid (1S,2R,4S,5R,6R,7S,9R,12R)-5,12-diacetoxy-4-benzoyloxy-2-hydroxy-2,6,10,10-tetramethyl-11-oxa-tricyclo[7.2.1.01,6]dodec-7-yl ester	KI	2920 nM
30-ethyl-33-[(E)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone	IC50	3100 nM	US-9090657: Compound and methods for its production
3,9-di(tert.)butoxycarbonyl-1,7-dihydroxymethyl-6,12-diphenyl-3,9-diazahexacyclo[6.4.0.0(2.7)0(4.11)0(5.10)]dodecane	IC50	3200 nM
CHEMBL2042909	IC50	3600 nM
nicotinic acid (1S,2R,3S,4S,5R,6R,7S,9R,12R)-4,12-diacetoxy-5,7-bis-benzoyloxy-2-hydroxy-2,6,10,10-tetramethyl-11-oxa-tricyclo[7.2.1.01,6]dodec-3-yl ester	KI	3750 nM
1,7-dihydroxymethyl-3,9-dimethoxycarbonyl-6,12-diphenyl-3,9-diazahexacyclo[6.4.0.0(2.7)0(4.11)0(5.10)]dodecane	IC50	3800 nM
(1S,2R,4S,5R,6R,7S,9R,12R)-5,12-bis(acetyloxy)-4-[(furan-2-yl)carbonyloxy]-2-hydroxy-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0^{1,6}]dodecan-7-yl furan-2-carboxylate	KI	4130 nM
CHEMBL209128	IC50	4230 nM
benzoic acid (1S,2R,4S,5R,6R,7S,9R,12R)-4,5,12-triacetoxy-6-acetoxymethyl-2-hydroxy-2,10,10-trimethyl-11-oxa-tricyclo[7.2.1.01,6]dodec-7-yl ester	KI	4390 nM
CHEMBL2042914	IC50	4500 nM
(1S,2R,4S,5R,6R,7S,9R,12R)-12-(acetyloxy)-6-[(acetyloxy)methyl]-4,5-bis[(furan-2-yl)carbonyloxy]-2-hydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0^{1,6}]dodecan-7-yl furan-2-carboxylate	KI	4510 nM
CHEMBL2042910	IC50	4600 nM
furan-2-carboxylic acid (1S,2R,4S,5R,6R,7S,9R,12R)-5-acetoxy-4-benzoyloxy-12-dodecanoyloxy-2-hydroxy-2,6,10,10-tetramethyl-11-oxa-tricyclo[7.2.1.01,6]dodec-7-yl ester	KI	5160 nM
CHEMBL209166	IC50	5720 nM
Benzoic acid (1S,2R,4S,5R,6S,7S,9R,12R)-4,7,12-triacetoxy-6-acetoxymethyl-2,10,10-trimethyl-8-oxo-11-oxa-tricyclo[7.2.1.01,6]dodec-5-yl ester	KI	5740 nM
CHEMBL2042908	IC50	6200 nM
acetic acid (1S,2R,3S,4R,5R,6R,7S,8R,9R,10R,12R)-3,5,7,8,12-pentaacetoxy-6,10-bis-acetoxymethyl-2-hydroxy-2,10-dimethyl-11-oxa-tricyclo[7.2.1.01,6]dodec-4-yl ester	KI	6970 nM
1,7-dihydroxymethyl-3,9-dimethyl-6,12-diphenyl-3,9-diazahexacyclo[6.4.0.0 2.7.0 4.11.0. 5.10]dodecane	IC50	7500 nM
Acetic acid (1S,2R,4S,5R,6S,7S,9R,12R)-4,5,7-triacetoxy-6-acetoxymethyl-2,10,10-trimethyl-8-oxo-11-oxa-tricyclo[7.2.1.01,6]dodec-12-yl ester	KI	9830 nM
(2S,5S,8S)-14-methoxy-5-methyl-2-(2-methylpropyl)-3,6,17-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),11,13,15-tetraene-4,7-dione	IC50	15400 nM	US-9695174: Inhibitor of breast cancer resistance protein (BCRP)
25,30-diethyl-33-[(E)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,27,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21,24-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone	IC50	16000 nM	US-9090657: Compound and methods for its production
benzoic acid (1S,2R,4S,5R,6S,7S,9R,12R)-4,12-diacetoxy-6-acetoxymethyl5-hydroxy-2,10,10-trimethyl-8-oxo-11-oxa-tricyclo[7.2.1.01,6]dodec-7-yl ester	KI	18400 nM
1,7-dihydroxymethyl-6,12-diphenyl-3,9-diphenoxycarbonyl-3,9-diazahexacyclo[6.4.0.0(2.7)0(4.11)0(5.10)]dodecane	IC50	21000 nM
nicotinic acid (1S,2R,3S,4S,5R,6R,7S,9R,12R)-4,12-diacetoxy-5-benzoyloxy-2-hydroxy-2,6,10,10-tetramethyl-7-(3-phenyl-acryloyloxy)-11-oxa-tricyclo[7.2.1.01,6]dodec-3-yl ester	KI	25000 nM
furan-2-carboxylic acid (1S,2R,4S,5R,6R,7S,9R,12R)-4,5,12-triacetoxy-2-hydroxy-2,6,10,10-tetramethyl-11-oxa-tricyclo[7.2.1.01,6]dodec-7-yl ester	KI	100000 nM

ChEMBL bioactivities

3019 potent at pChembl≥5 of 3741 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
10.99	EC50	0.01026	nM	CHEMBL2136603
10.99	EC50	0.01015	nM	CHEMBL2134144
10.98	EC50	0.01046	nM	CHEMBL2132650
10.98	EC50	0.01057	nM	CHEMBL2138767
10.96	EC50	0.01096	nM	CHEMBL2132526
10.93	EC50	0.01184	nM	CHEMBL2136710
10.93	EC50	0.01177	nM	CHEMBL2137849
10.89	EC50	0.01283	nM	CHEMBL1900518
10.87	EC50	0.01349	nM	CHEMBL2135811
10.87	EC50	0.01351	nM	CHEMBL2132316
10.83	EC50	0.01481	nM	CHEMBL2141711
10.81	EC50	0.01533	nM	CHEMBL2142519
10.80	EC50	0.01574	nM	CHEMBL2136218
10.80	EC50	0.01582	nM	CHEMBL2142058
10.78	EC50	0.01661	nM	CHEMBL2137696
10.77	EC50	0.01686	nM	CHEMBL2139052
10.76	EC50	0.01727	nM	CHEMBL1884699
10.76	EC50	0.0175	nM	CHEMBL2134880
10.75	EC50	0.01797	nM	CHEMBL2138028
10.74	EC50	0.01816	nM	CHEMBL2135227
10.74	EC50	0.01824	nM	CHEMBL2137680
10.71	EC50	0.0196	nM	CHEMBL2135699
10.71	EC50	0.01956	nM	CHEMBL2132333
10.66	EC50	0.02166	nM	CHEMBL2145384
10.63	EC50	0.02338	nM	CHEMBL2133117
10.57	EC50	0.02676	nM	CHEMBL2138719
10.56	EC50	0.02749	nM	CHEMBL2141371
10.54	EC50	0.02882	nM	CHEMBL2140166
10.52	IC50	0.03	nM	CHEMBL4161103
10.49	EC50	0.03209	nM	CHEMBL2140410
10.44	EC50	0.03638	nM	CHEMBL2134322
10.40	IC50	0.04	nM	CHEMBL4863423
10.24	EC50	0.05729	nM	CHEMBL2137688
10.22	EC50	0.06041	nM	CHEMBL2144131
10.21	EC50	0.06117	nM	CHEMBL2139235
10.19	EC50	0.06443	nM	CHEMBL2142245
10.15	IC50	0.07	nM	CHEMBL4568985
9.90	EC50	0.1261	nM	CHEMBL2130718
9.84	EC50	0.1432	nM	CHEMBL2132529
9.84	EC50	0.1443	nM	CHEMBL2133411
9.83	EC50	0.1485	nM	CHEMBL2133727
9.82	EC50	0.1524	nM	CHEMBL2142216
9.74	EC50	0.1832	nM	CHEMBL2137928
9.67	EC50	0.2157	nM	CHEMBL2132766
9.59	IC50	0.26	nM	TARIQUIDAR
9.53	EC50	0.2986	nM	CHEMBL2139350
9.28	EC50	0.5212	nM	CHEMBL2133413
9.26	EC50	0.5509	nM	CHEMBL2143184
9.22	EC50	0.6	nM	CHEMBL4585968
9.22	IC50	0.6	nM	ENCEQUIDAR

PubChem BioAssay actives

1103 with measured affinity, of 6100 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
benzyl (1R,2R,10S,11R,14R,15S,18S,23S)-10-(hydroxymethyl)-2,10,14,15,21,21-hexamethyl-5,8-diazahexacyclo[12.12.0.02,11.04,9.015,24.018,23]hexacosa-4,6,8,24-tetraene-18-carboxylate	1761215: Reversal of P-glycoprotein mediated multidrug resistance in human MCF-7T cells assessed as reversal of resistance to vincristine-induced cytotoxicity by measuring vincristine IC50 at 10 uM measured after 72 hrs by MTT assay	ic50	<0.0001	uM
2-[2-oxo-2-[[1-phenyl-3-(2,4,5-trimethylphenyl)pyrazol-5-yl]amino]ethyl]sulfanyl-N-(3,4,5-trimethoxyphenyl)acetamide	1558784: Reversal of P-gp mediated multidrug resistance in human DU145-TxR cells overexpressing P-gp assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM after 48 hrs by MTT assay (Rvb = 2120 nM)	ic50	0.0001	uM
N-[2-[[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]carbamoyl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide	1761215: Reversal of P-glycoprotein mediated multidrug resistance in human MCF-7T cells assessed as reversal of resistance to vincristine-induced cytotoxicity by measuring vincristine IC50 at 10 uM measured after 72 hrs by MTT assay	ic50	0.0002	uM
N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxochromene-2-carboxamide	1766766: Inhibition of paclitaxel stimulated- P-gp ATPase activity (unknown origin)	ic50	0.0006	uM
3-[2-[4-[4-[(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)methyl]phenyl]phenoxy]ethoxy]-4-methoxy-1,2,5-oxadiazole	1626583: Inhibition of MDR1 (unknown origin) expressed in MDCK cells assessed as decrease in calcein-AM transport after 30 mins by fluorescence assay	ec50	0.0006	uM
N-(1,3-benzothiazol-6-yl)-2-[2-oxo-2-[[1-phenyl-3-(2,4,5-trimethylphenyl)pyrazol-5-yl]amino]ethyl]sulfanylacetamide	1558784: Reversal of P-gp mediated multidrug resistance in human DU145-TxR cells overexpressing P-gp assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM after 48 hrs by MTT assay (Rvb = 2120 nM)	ic50	0.0008	uM
[6-(4-methoxyphenyl)-2-[(2-methylbenzoyl)amino]-3-thiophen-2-yl-1-benzofuran-4-yl] acetate	1739809: Inhibition of ABCB1 in FLp-In-293 cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 5 uM measured after 72 hrs by SRB assay (Rvb = 6 +/- 0.2 nM)	ic50	0.0008	uM
[2-[(2-chlorobenzoyl)amino]-6-(4-methoxyphenyl)-3-thiophen-2-yl-1-benzofuran-4-yl] acetate	1739809: Inhibition of ABCB1 in FLp-In-293 cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 5 uM measured after 72 hrs by SRB assay (Rvb = 6 +/- 0.2 nM)	ic50	0.0008	uM
3-(benzenesulfinyl)-4-[2-[4-[4-[(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)methyl]phenyl]phenoxy]ethoxy]-1,2,5-oxadiazole	1626583: Inhibition of MDR1 (unknown origin) expressed in MDCK cells assessed as decrease in calcein-AM transport after 30 mins by fluorescence assay	ec50	0.0009	uM
3-[3-[4-[4-[(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)methyl]phenyl]phenoxy]propoxy]-4-phenylmethoxy-1,2,5-oxadiazole	1626583: Inhibition of MDR1 (unknown origin) expressed in MDCK cells assessed as decrease in calcein-AM transport after 30 mins by fluorescence assay	ec50	0.0010	uM
10-[4-[4-(2-hydroxyethyl)piperazin-1-yl]butyl]-2,4-dimethylacridin-9-one	1446668: Inhibition of ABCB1 in human MCF7/ADR cells assessed as potentiation of vinblastine-induced cytotoxicity by measuring vinblastine IC50 at IC10 after 7 days by SRB assay	ic50	0.0013	uM
3-(benzenesulfinyl)-4-[3-[4-[4-[(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)methyl]phenyl]phenoxy]propoxy]-1,2,5-oxadiazole	1626583: Inhibition of MDR1 (unknown origin) expressed in MDCK cells assessed as decrease in calcein-AM transport after 30 mins by fluorescence assay	ec50	0.0013	uM
N-naphthalen-2-yl-2-[2-oxo-2-[[1-phenyl-3-(2,4,5-trimethylphenyl)pyrazol-5-yl]amino]ethyl]sulfanylacetamide	1558784: Reversal of P-gp mediated multidrug resistance in human DU145-TxR cells overexpressing P-gp assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM after 48 hrs by MTT assay (Rvb = 2120 nM)	ic50	0.0020	uM
[(2R,3S)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 4-fluoro-3-[(3,4,5-trimethoxybenzoyl)amino]benzoate	1228905: Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversible of paclitaxel resistance measured as IC50 for paclitaxel at 1 uM after 5 days by CellTiter 96 Aqueous assay	ic50	0.0027	uM
10-[4-[bis(2-hydroxyethyl)amino]butyl]-2,4-dimethylacridin-9-one	1446668: Inhibition of ABCB1 in human MCF7/ADR cells assessed as potentiation of vinblastine-induced cytotoxicity by measuring vinblastine IC50 at IC10 after 7 days by SRB assay	ic50	0.0031	uM
2-[4-[2-[2-(benzylamino)ethoxy]ethoxy]phenyl]chromen-4-one	1988156: Negative allosteric modulator activity at human P-gp G1114V mutant expressed in HEK293FT cells assessed as reversal of P-gp mediated PTX resistance by measuring paclitaxel IC50 incubated for 5 days by MTS assay (Rvb = 3.4 +/- 0.5 nM)	ic50	0.0035	uM
1-[5-bromo-2-(2-morpholin-4-ylethoxy)-4-phenylmethoxybenzoyl]-3,4-bis(3,4-dimethoxyphenyl)pyrrole-2,5-dione	1239230: Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as paclitaxel IC50 for cell growth inhibition at 1 uM after 5 days by MTS assay	ic50	0.0035	uM
[(2R,3R)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-3,4-dihydro-2H-chromen-3-yl] (E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoate	1228905: Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversible of paclitaxel resistance measured as IC50 for paclitaxel at 1 uM after 5 days by CellTiter 96 Aqueous assay	ic50	0.0037	uM
[2-[(3-fluorobenzoyl)amino]-6-(4-methoxyphenyl)-3-thiophen-2-yl-1-benzofuran-4-yl] acetate	1739809: Inhibition of ABCB1 in FLp-In-293 cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 5 uM measured after 72 hrs by SRB assay (Rvb = 6 +/- 0.2 nM)	ic50	0.0037	uM
N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-6-methyl-4-oxochromene-2-carboxamide	1766776: Inhibition of P-gp (unknown origin) expressed in MES-SA/DX5 cells assessed as increase in reversal of resistance to paclitaxel-induced cytotoxicity by measuring reduction in paclitaxel EC50 at 50 nM incubated for 72 hrs in presence of paclitaxel by SRB assay (Rvb = 294.6 nM)	ec50	0.0040	uM
6,7-dimethoxy-2-[4-[4-(4-methoxyphenyl)phenoxy]butyl]-3,4-dihydro-1H-isoquinoline	1170698: Inhibition of MDR1 (unknown origin) over-expressed in MDCK cells assessed as calcein accumulation incubated for 30 mins prior to Calcein-AM addition measured after 30 mins by fluorescence assay	ec50	0.0040	uM
2-[2-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-2-oxoethyl]sulfanyl-N-[1-phenyl-3-(2,4,5-trimethylphenyl)pyrazol-5-yl]acetamide	1558784: Reversal of P-gp mediated multidrug resistance in human DU145-TxR cells overexpressing P-gp assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM after 48 hrs by MTT assay (Rvb = 2120 nM)	ic50	0.0040	uM
10-[4-(diethylamino)butyl]-2,4-dimethylacridin-9-one	1446668: Inhibition of ABCB1 in human MCF7/ADR cells assessed as potentiation of vinblastine-induced cytotoxicity by measuring vinblastine IC50 at IC10 after 7 days by SRB assay	ic50	0.0040	uM
2,4-dimethyl-10-(4-morpholin-4-ylbutyl)acridin-9-one	1446668: Inhibition of ABCB1 in human MCF7/ADR cells assessed as potentiation of vinblastine-induced cytotoxicity by measuring vinblastine IC50 at IC10 after 7 days by SRB assay	ic50	0.0040	uM
[2-(diacetylamino)-6-(4-methoxyphenyl)-3-thiophen-2-yl-1-benzofuran-4-yl] acetate	1739809: Inhibition of ABCB1 in FLp-In-293 cells assessed as potentiation of vincristine-induced cytotoxicity by measuring vincristine IC50 at 5 uM measured after 72 hrs by SRB assay (Rvb = 6 +/- 0.2 nM)	ic50	0.0040	uM
[(2R,3S)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 4-fluoro-3-[[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]amino]benzoate	1228905: Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversible of paclitaxel resistance measured as IC50 for paclitaxel at 1 uM after 5 days by CellTiter 96 Aqueous assay	ic50	0.0042	uM
[(2R,3S)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3-[(3,4-dimethoxybenzoyl)amino]-4-fluorobenzoate	1228905: Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversible of paclitaxel resistance measured as IC50 for paclitaxel at 1 uM after 5 days by CellTiter 96 Aqueous assay	ic50	0.0046	uM
2-(1H-benzimidazol-2-ylmethylsulfanyl)-N-(4-fluorophenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine	1683992: Inhibition of ABCB1 in multidrug-resistant human KB-C2 cells assessed as increase in reversal of resistance to paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 20 uM pre-incubated for 4 hrs followed by paclitaxel addition and measured after 72 hrs by MTT assay (Rvb = 1886.37 +/- 243.05 nM)	ic50	0.0047	uM
N-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]-5-methoxy-9-oxo-10H-acridine-4-carboxamide	1766766: Inhibition of paclitaxel stimulated- P-gp ATPase activity (unknown origin)	ic50	0.0049	uM
2,4-dimethyl-10-(4-piperidin-1-ylbutyl)acridin-9-one	1446668: Inhibition of ABCB1 in human MCF7/ADR cells assessed as potentiation of vinblastine-induced cytotoxicity by measuring vinblastine IC50 at IC10 after 7 days by SRB assay	ic50	0.0050	uM
N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]quinoline-8-carboxamide	1766775: Inhibition of P-gp (unknown origin) expressed in MCF7 cells assessed as increase in reversal of resistance to paclitaxel-induced cytotoxicity by measuring reduction in paclitaxel EC50 at 50 nM incubated for 72 hrs in presence of paclitaxel by SRB assay (Rvb = 11.5 nM)	ec50	0.0054	uM
N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-5-methoxy-4-oxochromene-2-carboxamide	1766776: Inhibition of P-gp (unknown origin) expressed in MES-SA/DX5 cells assessed as increase in reversal of resistance to paclitaxel-induced cytotoxicity by measuring reduction in paclitaxel EC50 at 50 nM incubated for 72 hrs in presence of paclitaxel by SRB assay (Rvb = 294.6 nM)	ec50	0.0059	uM
5-bromo-N-[3-[2-oxo-2-[[1-phenyl-3-(2,4,5-trimethylphenyl)pyrazol-5-yl]amino]ethyl]sulfanylphenyl]pyridine-3-carboxamide	1558784: Reversal of P-gp mediated multidrug resistance in human DU145-TxR cells overexpressing P-gp assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM after 48 hrs by MTT assay (Rvb = 2120 nM)	ic50	0.0060	uM
[(2R,3R)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 4-fluoro-3-[[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]amino]benzoate	1228905: Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversible of paclitaxel resistance measured as IC50 for paclitaxel at 1 uM after 5 days by CellTiter 96 Aqueous assay	ic50	0.0062	uM
N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]thiophene-3-carboxamide	1766775: Inhibition of P-gp (unknown origin) expressed in MCF7 cells assessed as increase in reversal of resistance to paclitaxel-induced cytotoxicity by measuring reduction in paclitaxel EC50 at 50 nM incubated for 72 hrs in presence of paclitaxel by SRB assay (Rvb = 11.5 nM)	ec50	0.0064	uM
1-[5-bromo-2-(2-hydroxyethoxy)-4-phenylmethoxybenzoyl]-3,4-bis(3,4-dimethoxyphenyl)pyrrole-2,5-dione	1239230: Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as paclitaxel IC50 for cell growth inhibition at 1 uM after 5 days by MTS assay	ic50	0.0065	uM
[(2R,3S)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3-[[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]-4-fluorobenzoate	1228905: Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversible of paclitaxel resistance measured as IC50 for paclitaxel at 1 uM after 5 days by CellTiter 96 Aqueous assay	ic50	0.0066	uM
benzyl (2Z)-2-[(3R,4S,5S,8S,9S,10S,11R,13R,14S,16S)-16-acetyloxy-3,11-dihydroxy-4,8,10,14-tetramethyl-2,3,4,5,6,7,9,11,12,13,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ylidene]-6-methylhept-5-enoate	1566020: Reversal of P-gp-mediated multidrug resistance in human KBV cells assessed as potentiation of paclitaxel-induced cytotoxicity by measuring paclitaxel IC50 at 10 uM after 72 hrs by MTT assay (Rvb = 352.31 +/- 10.9 nM)	ic50	0.0070	uM
N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-6-fluoro-4-oxochromene-2-carboxamide	1766776: Inhibition of P-gp (unknown origin) expressed in MES-SA/DX5 cells assessed as increase in reversal of resistance to paclitaxel-induced cytotoxicity by measuring reduction in paclitaxel EC50 at 50 nM incubated for 72 hrs in presence of paclitaxel by SRB assay (Rvb = 294.6 nM)	ec50	0.0075	uM
N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]isoquinoline-1-carboxamide	1766775: Inhibition of P-gp (unknown origin) expressed in MCF7 cells assessed as increase in reversal of resistance to paclitaxel-induced cytotoxicity by measuring reduction in paclitaxel EC50 at 50 nM incubated for 72 hrs in presence of paclitaxel by SRB assay (Rvb = 11.5 nM)	ec50	0.0076	uM
N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]benzamide	1766775: Inhibition of P-gp (unknown origin) expressed in MCF7 cells assessed as increase in reversal of resistance to paclitaxel-induced cytotoxicity by measuring reduction in paclitaxel EC50 at 50 nM incubated for 72 hrs in presence of paclitaxel by SRB assay (Rvb = 11.5 nM)	ec50	0.0077	uM
N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]quinoline-3-carboxamide	1766775: Inhibition of P-gp (unknown origin) expressed in MCF7 cells assessed as increase in reversal of resistance to paclitaxel-induced cytotoxicity by measuring reduction in paclitaxel EC50 at 50 nM incubated for 72 hrs in presence of paclitaxel by SRB assay (Rvb = 11.5 nM)	ec50	0.0079	uM
[(1S,2R,4R,5R,6S,7R,8S,9R,12R)-4,5,8-triacetyloxy-2,6,10,10-tetramethyl-12-[(E)-3-phenylprop-2-enoyl]oxy-11-oxatricyclo[7.2.1.01,6]dodecan-7-yl] benzoate	1753332: Reversal of P-gp-mediated multidrug resistance in human KB/VCR cells assessed as potentiation of vincristine-induced antiproliferative activity by measuring vincristine IC50 at 20 uM measured after 72 hrs by CCK8 assay (Rvb = 0.78 uM)	ic50	0.0080	uM
[(1S,2R,4S,5S,6S,7R,8S,9R,12R)-4,5,8-triacetyloxy-7-benzoyloxy-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.01,6]dodecan-12-yl] pyridine-3-carboxylate	1753332: Reversal of P-gp-mediated multidrug resistance in human KB/VCR cells assessed as potentiation of vincristine-induced antiproliferative activity by measuring vincristine IC50 at 20 uM measured after 72 hrs by CCK8 assay (Rvb = 0.78 uM)	ic50	0.0080	uM
[(1S,2R,5S,6S,7S,8R,9R,12R)-5,8,12-triacetyloxy-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.01,6]dodecan-7-yl] benzoate	1753332: Reversal of P-gp-mediated multidrug resistance in human KB/VCR cells assessed as potentiation of vincristine-induced antiproliferative activity by measuring vincristine IC50 at 20 uM measured after 72 hrs by CCK8 assay (Rvb = 0.78 uM)	ic50	0.0080	uM
10-[3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl]-2,4-dimethylacridin-9-one	1446668: Inhibition of ABCB1 in human MCF7/ADR cells assessed as potentiation of vinblastine-induced cytotoxicity by measuring vinblastine IC50 at IC10 after 7 days by SRB assay	ic50	0.0080	uM
[(2R,3R)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3-[[(E)-3-(3,4-dimethoxyphenyl)prop-2-enoyl]amino]-4-fluorobenzoate	1228905: Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversible of paclitaxel resistance measured as IC50 for paclitaxel at 1 uM after 5 days by CellTiter 96 Aqueous assay	ic50	0.0081	uM
N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]isoquinoline-3-carboxamide	1766775: Inhibition of P-gp (unknown origin) expressed in MCF7 cells assessed as increase in reversal of resistance to paclitaxel-induced cytotoxicity by measuring reduction in paclitaxel EC50 at 50 nM incubated for 72 hrs in presence of paclitaxel by SRB assay (Rvb = 11.5 nM)	ec50	0.0085	uM
[(2R,3R)-5,7-dimethoxy-2-(3,4,5-trimethoxyphenyl)-3,4-dihydro-2H-chromen-3-yl] (E)-3-(3,4-dimethoxyphenyl)prop-2-enoate	1228905: Modulation of P-gp (unknown origin) transfected in human MDA435/LCC6MDR cells assessed as reversible of paclitaxel resistance measured as IC50 for paclitaxel at 1 uM after 5 days by CellTiter 96 Aqueous assay	ic50	0.0087	uM
N-[2-[2-[4-[2-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)ethyl]phenyl]tetrazol-5-yl]-4,5-dimethoxyphenyl]-4-oxochromene-3-carboxamide	1766775: Inhibition of P-gp (unknown origin) expressed in MCF7 cells assessed as increase in reversal of resistance to paclitaxel-induced cytotoxicity by measuring reduction in paclitaxel EC50 at 50 nM incubated for 72 hrs in presence of paclitaxel by SRB assay (Rvb = 11.5 nM)	ec50	0.0090	uM

CTD chemical–gene interactions

655 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Doxorubicin	affects transport, decreases abundance, decreases secretion, increases cleavage, increases transport (+19 more)	79
Verapamil	decreases export, decreases reaction, affects reaction, affects binding, increases secretion (+18 more)	69
Rifampin	decreases reaction, increases expression, increases response to substance, affects activity, affects binding (+4 more)	40
Paclitaxel	affects reaction, decreases reaction, affects metabolic processing, affects response to substance, decreases uptake (+11 more)	35
Cyclosporine	increases secretion, increases activity, increases response to substance, affects export, affects binding (+16 more)	28
Digoxin	increases uptake, increases transport, affects transport, affects binding, increases reaction (+11 more)	25
Cisplatin	increases activity, increases cleavage, increases expression, increases reaction, increases acetylation (+7 more)	18
valspodar	increases export, affects activity, decreases response to substance, decreases activity, decreases transport (+7 more)	17
Daunorubicin	affects activity, decreases uptake, decreases activity, increases abundance, decreases expression (+12 more)	17
Vinblastine	affects response to substance, decreases reaction, increases export, increases reaction, decreases response to substance (+10 more)	17
Ketoconazole	decreases export, increases expression, affects transport, increases chemical synthesis, increases secretion (+8 more)	16
Vincristine	affects response to substance, decreases uptake, increases transport, decreases reaction, decreases expression (+9 more)	16
Quercetin	decreases reaction, increases cleavage, affects cotreatment, increases expression, decreases uptake (+7 more)	15
Docetaxel	increases reaction, affects response to substance, affects reaction, affects binding, increases expression (+5 more)	11
Methotrexate	affects reaction, decreases secretion, affects response to substance, affects cotreatment, increases response to substance (+2 more)	11
Elacridar	decreases uptake, increases reaction, decreases activity, affects transport, increases secretion (+6 more)	10
calcein AM	increases secretion, increases reaction, decreases export, affects binding, decreases reaction (+8 more)	10
Valproic Acid	decreases activity, decreases methylation, increases expression, affects response to substance, affects expression	10
Risperidone	increases transport, decreases export, decreases reaction, decreases activity, affects abundance (+2 more)	10
Resveratrol	affects binding, increases activity, decreases expression, increases uptake, decreases reaction (+4 more)	9
Arsenic Trioxide	decreases expression, increases expression	9
Phenobarbital	affects expression, decreases activity, increases expression	9
Colchicine	affects transport, decreases response to substance, increases export, decreases reaction, increases activity (+2 more)	8
Curcumin	affects response to substance, decreases response to substance, affects cotreatment, decreases expression, decreases reaction (+3 more)	8
bisphenol A	affects reaction, increases expression, affects expression, increases methylation	7
zosuquidar trihydrochloride	affects reaction, decreases reaction, decreases response to substance, increases export, increases transport (+4 more)	7
Fluorouracil	affects cotreatment, affects response to substance, decreases response to substance, increases expression, decreases expression	7
Phenytoin	increases metabolic processing, decreases activity, affects abundance, affects response to substance	7
Rhodamine 123	increases reaction, increases export, decreases activity, decreases export, decreases reaction (+1 more)	7
Adenosine Triphosphate	increases activity, affects reaction, affects binding, increases hydrolysis, increases reaction	6

ChEMBL screening assays

3063 unique, capped per target: 2135 binding, 746 functional, 182 admet

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL3411931	Binding	Inhibition of MDR1/MRP1 overexpressed in doxorubicin-resistant human HL60R cells assessed as DXR accumulation at 10 uM incubated for 2 hrs prior to DXR challenge measured after 2 hrs by fluorescence assay relative to control	Design, synthesis and biological profile of new inhibitors of multidrug resistance associated proteins carrying a polycyclic scaffold. — Eur J Med Chem
CHEMBL1106243	ADMET	Effect on human MDR1-mediated drug transport assessed as efflux ratio of permeability from basolateral to apical side to apical to basolateral side	Hydroxy cycloalkyl fused pyridone carboxylic acid M(1) positive allosteric modulators. — Bioorg Med Chem Lett
CHEMBL1738379	Functional	PubChem BioAssay. Dose Response for ABC transporter inhibitors: specifically ABCB1 screen, ABCG2 counter-screen. (Class of assay: confirmatory)	PubChem BioAssay data set

Cellosaurus cell lines

46 cell lines: 32 cancer cell line, 10 spontaneously immortalized cell line, 2 transformed cell line, 2 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_0E37	MV522/MDR1	Cancer cell line	Female
CVCL_1D80	KB-C1.5	Cancer cell line	Female
CVCL_1D81	KB-C2.5	Cancer cell line	Female
CVCL_6C41	IPEC-J2 MDR1	Spontaneously immortalized cell line	Sex unspecified
CVCL_A2JZ	MDCK2-ABCB1	Spontaneously immortalized cell line	Female
CVCL_A2KA	MDCK-hMDR1 cMDR1-KO	Spontaneously immortalized cell line	Female
CVCL_A5BB	SW1573/S1(MDR1)	Cancer cell line	Female
CVCL_A9MA	12D7-MDR1	Cancer cell line	Female
CVCL_B5ZQ	SA7K MDR1 KO	Transformed cell line	Female
CVCL_B5ZT	C2BBe1 MDR1 KO	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT03590197	PHASE4	COMPLETED	Effect of Melatonin on Seizure Outcome, Neuronal Damage and Quality of Life in Patients With Generalized Epilepsy
NCT03940326	PHASE4	COMPLETED	Levetiracetam Versus Valproate in Idiopathic Generalized Tonic-clonic Seizures
NCT00365508	PHASE4	COMPLETED	Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking
NCT00558155	PHASE4	COMPLETED	The Impact of Immunostimulating Nutrition on the Outcome of Surgery
NCT00576940	PHASE4	COMPLETED	Standard and Immunostimulating Enteral Nutrition in Surgical Patients
NCT00666978	PHASE4	COMPLETED	Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking
NCT01038154	PHASE4	UNKNOWN	Study to Evaluate the Efficacy of Pravastatin on Survival and Recurrence of Advanced Gastroesophageal Cancer
NCT01234272	PHASE4	COMPLETED	Comparison of the Analgesic Effect Between Intrathecal Morphine and IV-fentanyl Patient Controlled Analgesia (ITM-IVPCA) and Epidural PCA (PCEA) in Patients Undergoing Gastrectomy -Randomized Allocation Study-
NCT01260194	PHASE4	TERMINATED	A Study of Herceptin (Trastuzumab) in Combination With Standard Chemotherapy in Patients With HER Positive Metastatic Gastric Cancer
NCT01271582	PHASE4	UNKNOWN	Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
NCT01401075	PHASE4	COMPLETED	RCT With Adjuvant Mistletoe Treatment in Gastric Cancer Patients
NCT01471756	PHASE4	COMPLETED	Improving Complete Endoscopic Mucosal Resection (EMR) of Colorectal Neoplasia
NCT01766765	PHASE4	UNKNOWN	Early Jejunostomy Nutrition Minimizes Time to Chemotherapy
NCT01910948	PHASE4	UNKNOWN	Perioperative Application of Omega-3 Polyunsaturated Fatty Acids in Gastric Cancer Patients
NCT01927328	PHASE4	UNKNOWN	Iron Replacement in Oesophagogastric Neoplasia
NCT01962272	PHASE4	COMPLETED	The Effect of Nutritional Counseling for Cancer Patients
NCT01962376	PHASE4	UNKNOWN	Preoperative Chemotherapy With Bevacizumab For Potentially Resectable Gastric Cancer With Liver Metastasis
NCT02047994	PHASE4	RECRUITING	Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality
NCT02235246	PHASE4	COMPLETED	The Effect of Perioperative Intravenous Magnesium on Pain After Endoscopic Submucosal Dissection for Gastric Neoplasm: Prospective Randomized Double-blind Placebo Controlled Study
NCT02366819	PHASE4	SUSPENDED	Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
NCT02401971	PHASE4	UNKNOWN	Irinotecan Plus Thalidomide in Second Line Advanced Gastric Cancer
NCT02458573	PHASE4	COMPLETED	Comparison of the Effects of Continuous Epidural Analgesia and Continuous Intravenous Analgesia on Postoperative Bowel Movement in Patients Undergoing Laparoscopic Gastrectomy
NCT02638584	PHASE4	COMPLETED	Effects of Ilaprazole on Ulcer Healing Rate and Prevention of Gastrointestinal Bleeding in the Patients Undergone ESD.
NCT02776527	PHASE4	UNKNOWN	A Clinical Trial of Maintenance Treatment of Apatinib in Advanced Gastric Cancer Patients Have Completed Postoprative Adjuvant Chemotherapy
NCT03384511	PHASE4	COMPLETED	The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
NCT03550482	PHASE4	COMPLETED	Oncoxin® and Quality of Life in Cancer Patients
NCT03609892	PHASE4	COMPLETED	Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy
NCT03642093	PHASE4	UNKNOWN	HOPE - A Study to Evaluate the Effect of a Prehabilitation Program on GI Cancer Patients Planning to Undergo Surgery
NCT03733639	PHASE4	UNKNOWN	Tisseel® as a Reinforcement of Esophagojejunal Anastomoses
NCT04168346	PHASE4	NOT_YET_RECRUITING	Preoperative Intravenous Iron Therapy in Patients With Gastric Cancer
NCT04209933	PHASE4	COMPLETED	Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies
NCT04591028	PHASE4	WITHDRAWN	A Study to Evaluate Indocyanine Green Lymphangiography to Improve Lymphadenectomy in Gastric Cancer Patients
NCT04607057	PHASE4	UNKNOWN	Supplemental Parenteral Nutrition During Postgastrectomy in Nutritionally at Risk Patient
NCT04660123	PHASE4	COMPLETED	A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication
NCT04678492	PHASE4	COMPLETED	Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
NCT04697186	PHASE4	COMPLETED	Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy
NCT05029453	PHASE4	UNKNOWN	Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy
NCT05183126	PHASE4	RECRUITING	Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
NCT05354856	PHASE4	TERMINATED	The Effect of Chemoradiotherapy on Gastric Perfusion in Patients With Gastric Cancer.
NCT05410535	PHASE4	COMPLETED	To Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gasterectomy